In a move that puts an end to the GM-derived vehicle only a few years after its introduction, the Honda has put the Honda ...

The collaboration started in the first quarter of 2023, when RM TOHCELLO tested initial samples of PureFive resin.

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd). The ...

Introduction: Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers cases with 40-50% of them having mutations in EGFR and KRAS. Although approved EGFR inhibitors (osimertinib) and KRAS ...

Dato-DXd and imlunestrant offer new treatment options for HR-positive, HER2-negative breast cancer, targeting TROP2 and ESR1 mutations, respectively. Zongertinib, a selective HER2 inhibitor, shows ...

The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% ...

T-DXd significantly improves progression-free and overall survival compared to T-DM1 in HER2-positive metastatic breast cancer, with a favorable safety profile. Real-world data show T-DXd's ...

The FDA has approved trastuzumab deruxtecan (T-DXd; Enhertu, Daiichi Sankyo/AstraZeneca) in combination with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast ...

Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...

R-DXd targets CDH6 in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers, showing a 46% objective response rate in a phase 1 trial. FDA breakthrough therapy designation aims to ...